Eicosapentaenoic acid (EPA, omega-3 free fatty acid)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-OMEGA-3-EPA |
|---|---|
| Type | Drug |
| Aliases | EPAEicosapentaenoic acid (EPA)EpadelIcosapent ethylOmega-3 EPAVascepa (icosapent ethyl)Ейкозапентаєнова кислота (EPA, омега-3) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Omega-3 polyunsaturated fatty acid (purified EPA ester) |
|---|---|
| Mechanism | Long-chain omega-3 polyunsaturated fatty acid that competes with arachidonic acid as substrate for cyclooxygenase and lipoxygenase enzymes, shifting eicosanoid production toward less inflammatory 3-series prostaglandins and 5-series leukotrienes; modulates membrane fluidity and signaling. In familial adenomatous polyposis (FAP), small RCTs (e.g., West 2010 — Cancer Prevention Research) suggest EPA reduces duodenal-polyp burden. Cancer-prevention evidence outside FAP is limited and inconsistent (no benefit in colon polyp prevention per VITAL or seAFOod trials). |
| Typical dosing | Cancer-prevention research context (FAP duodenal polyposis): ~4 g/day EPA (typically as 2 g BID free fatty acid or icosapent ethyl). Hypertriglyceridemia: 4 g/day (2 capsules BID 1 g each, icosapent ethyl). Take with food. Note FAP cancer-prevention dose has only RCT-trial support, not FDA labeling. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. RESEARCH-CONTEXT cancer-prevention use only. In FAP, small RCTs suggest EPA reduces duodenal-polyp burden but does not replace surveillance endoscopy + polypectomy or prophylactic surgery decisions. No proven benefit in general-population colon polyp prevention (VITAL, seAFOod). Not currently NCCN/ESMO/InSiGHT guideline-recommended as standard FAP intervention — adjunct only under specialist hereditary-cancer center management. Source cited (SRC-NCCN-BCELL-2025) is closest in-KB until dedicated FAP-EPA-trial source (West 2010 et al.) lands in source-stub workstream.
Used By
Drug
DRUG-OMEGA-3-FATTY-ACIDS-CHEMOPREVENTION- Omega-3 fatty acids EPA+DHA (general-population cancer chemoprevention research context)